Fundamental Research Division
The DRF at the CEA assemble approximately 6,000 scientists since January 2016.
News | Press release | Health ＆ life sciences | Defence ＆ security
The CEA coordinates the European project COUNTERACT which aims to reinforce the European Union’s preparedness for nuclear, radiological, biological and chemical (NRBC) threats.
COUNTERACT is co-funded for 49 million euros by the European Defence Fund1 and aims to set up pre-clinical and clinical studies on the safety and efficiency of medical countermeasures targeting NRBC-type threats.
The project will cover a four-year period and started in December 2022. This project brings together key European players: 26 partners from 11 EU Member states (five universities; three technological research bodies, including the CEA; ten public research institutes; eight SME and start-ups).
COUNTERACT aims to prepare the European Union to face current and future NRBC threats with the support of a European public-private ecosystem. The CEA will provide its full range of confirmed scientific expertise, renowned in the fields of virology, immunology, pharmacology and radiobiology, for this large-scale project.” Roger Le Grand, Idmit2 director at CEA and COUNTERACT project coordinator.
COUNTERACT brings together research teams with unique expertise at the European level and the medicine industries for the purpose of developing medical countermeasures to cover NRBC threats. These countermeasures must be effective, and quick and easy to deploy. With COUNTERACT, our aim is also to structure European players in this sector into a responsive and flexible network able to speed up the pre-clinical and clinical development of medical countermeasures.” Nathalie Bosquet, deputy director of the COUNTERACT project.
1The Fund supports competitive and collaborative projects throughout the entire cycle of research and development for a bigger impact on the European defence capability and industrial landscape. To learn more: The European Defence Fund (EDF) (europa.eu).
2Infectious Disease Models and Innovative Therapies, mixed research unit set up at the CEA site in Fontenay-aux-Roses.
CEA is a French government-funded technological research organisation in four main areas: low-carbon energies, defense and security, information technologies and health technologies. A prominent player in the European Research Area, it is involved in setting up collaborative projects with many partners around the world.